Board Member

• Oct 2023 - Present

Co-Founder and Advisor

• Apr 2019 - Present

Actively engaged in acquisition and development of novel entities to meet patient needs in neurosciences. Actively engaged in acquisition and development of novel entities to meet patient needs in neurosciences.

President

• May 2018 - Present

Chief, Division of Clinical Pharmacology and Senior Research Professor of Medicine

• Nov 2018 - May 2022

Advancing the science of Clinical Pharmacology and providing a home for world class research, world class researchers, and education in drug discovery and development in the largest School of Medicine in the United States at Indiana University. Advancing the science of Clinical Pharmacology and providing a home for world class research, world class researchers, and education in drug discovery and development in the largest School of Medicine in the United States at Indiana University.

Vice President of Research Operations and COO Lilly Research Laboratories (LRL) and LRL Europe

• 2007 - Jan 2018

Reports to President of Lilly Research Laboratories. Vice-chair of portfolio management committee responsible for scientific and technical review of portfolio through Phase 2. Co-chair of Medical Plans Review Committee. Responsible for due diligence assessment prior to in-licensing of assets and technology for Lilly. Lead group of scientists with direct accountability for compliance, out-sourcing, academic collaborations, capital investment planning, competitive analysis, business process… Show more Reports to President of Lilly Research Laboratories. Vice-chair of portfolio management committee responsible for scientific and technical review of portfolio through Phase 2. Co-chair of Medical Plans Review Committee. Responsible for due diligence assessment prior to in-licensing of assets and technology for Lilly. Lead group of scientists with direct accountability for compliance, out-sourcing, academic collaborations, capital investment planning, competitive analysis, business process improvement, six sigma, and global research management. Lead business process integration efforts for strategic acquisitions and divestitures. Responsible for strategy and operations of Lilly Research Laboratories in Europe. Scientific advisor for Lilly venture investment.

Vice President of Toxicology, Drug Dispositon, Pharmacokinetics and LRL Europe

• Oct 2001 - 2007

Senior leadership and oversight of the Toxicology and Drug Disposition Division. Recruited and hired scientists. Led discussion and scientific design of ADME studies for portfolio assets. Interfaced with senior research and development leadership to deliver Lilly's portfolio of innovation. Managed the global business and scientific support. Oversight of outsourcing pre-clinical studies to support development. Implemented a discovery support strategy in order to increase the technical… Show more Senior leadership and oversight of the Toxicology and Drug Disposition Division. Recruited and hired scientists. Led discussion and scientific design of ADME studies for portfolio assets. Interfaced with senior research and development leadership to deliver Lilly's portfolio of innovation. Managed the global business and scientific support. Oversight of outsourcing pre-clinical studies to support development. Implemented a discovery support strategy in order to increase the technical probability of success of molecules in development. Leader of pre-clinical portfolio governance committee from Lead Phase to Phase 2.

Executive Director of Toxicology and Drug Disposition Lilly Research Laboratories (LRL) and Europe

• 1998 - Oct 2001

Leader of scientific staff and strategic direction for Toxicology division. Led strategy and operational oversight of European research labs in England, Germany, Spain and Belgium.

Director, Drug Disposition and Biochemical Toxcology

• 1994 - 1998

Division leader of ADME and pharmacokinetic group supporting Lilly research and development portfolio. Managed audited functions and reviewed regulatory submissions supporting label claims and new product approvals. Senior leader of Investigative Toxicology group responsible for understanding mechanisms of toxicity of compounds in development. Led a cross functional research and development team to redesign the project management support of teams prior transition to Phase 3 development.

Head, Biochemical Toxicology

• 1992 - 1994

Leader of the Investigative Toxicology portion of the toxicology division.

Senior Pharmacologist

• 1990 - 1992

Designed and conducted pre-clinical ADME studies on Alzheimer's research projects and principal ADME investigator for the candidate selection of Viracept, an HIV protease inhibitor which eventually benefitted patients. Worked on cross functional teams to deliver project goals.

Senior Research Chemist

• May 1989 - Oct 1990

Clinical Drug Metabolism. Designed studies. Interpreted data. Created assays for clinical drug metabolism, distribution, absorption and elimination studies. Worked as drug metabolism representative to clinical development teams. Led a group of Research Scientists in comparative biotransformation studies. Clinical Drug Metabolism. Designed studies. Interpreted data. Created assays for clinical drug metabolism, distribution, absorption and elimination studies. Worked as drug metabolism representative to clinical development teams. Led a group of Research Scientists in comparative biotransformation studies.